Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer

被引:39
作者
Koishi, Kenji
Yoshikawa, Reigetsu
Tsujimura, Tohru
Hashimoto-Tamaoki, Tomoko
Kojima, Syoudou
Yanagi, Hidenori
Yamamura, Takehira
Fujiwara, Yoshinori
机构
[1] Hyogo Coll Med, Dept Surg 2, Nishinomiya, Hyogo 6638501, Japan
[2] Hyogo Coll Med, Inst Adv Med Sci, Nishinomiya, Hyogo 6638501, Japan
[3] Hyogo Coll Med, Dept Pathol 2, Nishinomiya, Hyogo 6638501, Japan
[4] Hyogo Coll Med, Dept Genet, Nishinomiya, Hyogo 6638501, Japan
关键词
CXC chemokine receptor-4; metastasis; chemoradiotherapy; esophageal cancer;
D O I
10.3748/wjg.v12.i47.7585
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To study the effect of CXC chemokine receptor-4 (CXCR4) expression. on disease progression and prognosis in esophageal cancer. METHODS: CXCR4 expression was evaluated in 37 patients with histologically confirmed esophageal squamous carcinomas (ESCC) undergoing preoperative chemoradiotherapy (CRT) by immunohistochemical staining. RESULTS: Eleven out of 37 ESCC patients showed a pathological complete response (CR) after CRT. CXCR4 protein expression was observed in cell cytoplasms of 13 tumors, and null expression was seen in 13 tumors. Distant recurrence was significantly more common in patients with positive CXCR4 expression (P = 0.0318). After a median follow-up time of 31.6 mo, 19 patients progressed (12 of 19 expressed positive CXCR4) and 11 died (10 of 11 expressed positive CXCR4). Overall survival was significantly correlated with lymph node metastasis (952.1 +/- 53.8 d in negative group vs 475.1 +/- 56.2 d in positive group, P = 0.023), distant metastasis (874.0 60.4 d in negative group vs 434.9 +/- 75.2 d in positive group, P = 0.014) and CRT (811.5 +/- 51.2 d in responder group vs 459.6 +/- 94.0 d in non-responder group, P = 0.00038) and further with an absence of CXCR4 expression or no residual tumor (959.8 51.0 d in null expression or no tumor group vs 412.0 +/- 57.1 d in positive expression group, P = 0.0001). CONCLUSION: Persistent positive CXCR4 expression is implicated in tumor aggressiveness and poor prognosis in ESCC after CRT, and preoperative CRT may improve the prognosis of ESCC via'CXCL12-CXCR4 signaling pathway. (c) 2006 The WIG Press. All rights reserved.
引用
收藏
页码:7585 / 7590
页数:6
相关论文
共 26 条
[1]  
Bachelder RE, 2002, CANCER RES, V62, P7203
[2]  
Bertolini F, 2002, CANCER RES, V62, P3106
[3]   The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry [J].
Bleul, CC ;
Farzan, M ;
Choe, H ;
Parolin, C ;
ClarkLewis, I ;
Sodroski, J ;
Springer, TA .
NATURE, 1996, 382 (6594) :829-833
[4]   High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia [J].
Crazzolara, R ;
Kreczy, A ;
Mann, G ;
Heitger, A ;
Eibl, G ;
Fink, FM ;
Möhle, R ;
Meister, B .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (03) :545-553
[5]   Rapid mobilization of CD34+cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma [J].
Devine, SM ;
Flomenberg, N ;
Vesole, DH ;
Liesveld, J ;
Weisdorf, D ;
Badel, K ;
Calandra, G ;
DiPersio, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1095-1102
[6]   The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone [J].
Flomenberg, N ;
Devine, SM ;
DiPersio, JF ;
Liesveld, JL ;
McCarty, JM ;
Rowley, SD ;
Vesole, DH ;
Badel, K ;
Calandra, G .
BLOOD, 2005, 106 (05) :1867-1874
[7]  
Fujiwara Y, 2005, ONCOL REP, V14, P1177
[8]   The α-chemokine, stromal cell-derived factor-1α, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways [J].
Ganju, RK ;
Brubaker, SA ;
Meyer, J ;
Dutt, P ;
Yang, YM ;
Qin, SX ;
Newman, W ;
Groopman, JE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (36) :23169-23175
[9]   Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers [J].
Hendrix, CW ;
Flexner, C ;
MacFarland, RT ;
Giandomenico, C ;
Fuchs, EJ ;
Redpath, E ;
Bridger, G ;
Henson, GW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (06) :1667-1673
[10]  
ISONO K, 1991, ONCOLOGY, V48, P411